NICE flip-flops to back Bristol-Myers' Opdivo in head and neck cancer despite data 'uncertainties'

13th October 2017 Uncategorised 0

Back in April, England’s cost watchdogs said they wouldn’t cover Bristol-Myers Squibb’s Opdivo in head and neck cancer due to “uncertain” clinical evidence. Now, though, they’re singing a different tune.

More: NICE flip-flops to back Bristol-Myers' Opdivo in head and neck cancer despite data 'uncertainties'
Source: fierce